American Well Earnings Call Transcripts
Fiscal Year 2026
-
The company has transformed to focus on payer and government markets, achieving strong Q1 results with higher subscription and visit revenues, improved margins, and significant cost reductions. Major government contracts and payer renewals are set to drive growth and margin expansion, with AI adoption supporting further efficiencies.
-
Revenue declined 18% year-over-year in Q1 2026, but gross margin remained strong and cost discipline led to a significant reduction in losses. Renewals and pipeline growth were robust, with confidence in achieving cash flow breakeven in Q4 and multi-year growth ahead.
-
Virtual healthcare is challenged by market fragmentation, but growth is driven by payer and government segments. Major contracts like Elevance and DHA support revenue stability, with AI integration enhancing efficiency. 2026 guidance targets $195–$205M revenue and EBITDA breakeven, with strong cash reserves and new government opportunities expected.
Fiscal Year 2025
-
2025 saw a strategic transformation to a unified tech platform, with divestitures and cost reductions leading to improved margins and a higher-quality revenue base. 2026 guidance projects lower revenue but improved profitability, with positive cash flow expected in Q4.
-
Q3 revenue and adjusted EBITDA exceeded expectations, driven by higher subscription revenue, cost efficiencies, and a shift to a more software-focused model. The company is divesting non-core assets, investing in AI, and expects positive cash flow from operations by end of 2026.
-
The company is accelerating its shift to a technology-enabled care model, focusing on unified, AI-driven platforms and high-margin software solutions. Recent government wins, cost reductions, and a clear mission position it for growth and profitability by 2026.
-
Q2 2025 featured strong revenue growth, margin expansion, and a key MHS contract extension, though guidance was revised lower due to government budget constraints. Cost initiatives and a focus on subscription software are driving improved EBITDA and a path to positive cash flow in 2026.
-
The meeting covered director elections, auditor ratification, and executive compensation approval, with all proposals recommended by the board. Quorum was established, voting was conducted online, and final results will be filed with the SEC.
-
Q1 2025 saw strong software revenue growth, margin expansion, and improved adjusted EBITDA, driven by large-scale deployments and cost reductions. Guidance for 2025 is reiterated, with positive cash flow from operations targeted for 2026, contingent on DHA contract renewal.
-
Digital health adoption is accelerating, with a major SaaS deployment for the Defense Health Agency nearly complete and expected to drive significant revenue growth. The platform’s unified approach is resonating with payers and providers, while cost reductions and a strong cash position support a path to profitability by 2026.
Fiscal Year 2024
-
2024 saw a strategic refocus, cost reductions, and strong subscription revenue growth, especially from the DHA contract. Guidance for 2025 projects a return to growth, margin expansion, and a path to positive cash flow in 2026, with a robust cash position and high revenue visibility.
-
The company is accelerating its shift to risk-based, value-driven care models, investing in digital infrastructure, and focusing on profitable subscription revenue. Progress on a major DHA contract and global enterprise expansion is expected to drive high-margin growth.
-
Q3 revenue was flat year-over-year at $61M, with improved Adjusted EBITDA and strong cash reserves. Cost realignment and subscription growth position the business for higher-margin revenue in 2025, while the DHA contract remains on track for enterprise deployment by year-end.
-
The company has transformed its strategy to focus on enabling digitally enabled care through its Converge platform, highlighted by a major DHA deployment and a shift to high-margin, scalable technology. Financial outlook is strong, with rising margins, cost reductions, and profitability targeted by 2026. AI integration and market demand for digital-first care underpin future growth.
-
Q2 saw 5% revenue growth, a 660 bps gross margin increase, and a 23% improvement in Adjusted EBITDA. Cost efficiencies and major contract wins drove improved 2024 guidance, with break-even targeted for 2026 and strong progress on the DHA initiative.
-
The meeting covered director elections, auditor ratification, executive compensation, and a reverse stock split proposal, with all items recommended by the board. Voting results will be disclosed in a Form 8-K filing within four business days.